Institutional members access full text with Ovid®

Share this article on:

Meningioma in Breast Cancer Patients: Population-based Analysis of Clinicopathologic Characteristics

Milano, Michael T. MD, PhD; Grossman, Craig E. MD, PhD

American Journal of Clinical Oncology: February 2017 - Volume 40 - Issue 1 - p 11–16
doi: 10.1097/COC.0000000000000052
Original Articles: Central Nervous System

Objectives: Although an association between meningioma and breast cancer (BC) has been postulated, clear mechanisms remain obscure. By conducting population-based analyses in women with both BC and meningioma, hypothesis-generating causal links were pursued.

Methods: Using the US SEER 18 registry (2004 to 2009), clinicopathologic and demographic characteristics from cohorts of women with only BC (n=279,821) or meningioma (n=19,570) diagnoses were compared with 412 women with both diagnoses (BC-meningioma).

Results: BC diagnosis preceded meningioma by >2 months in 48% of women; 20% had synchronous (within 2 mo) disease. Median meningioma size was 1.9 and 2.4 cm in the BC-meningioma and meningioma cohorts, respectively (P=0.0009). Among BC-meningioma patients, meningioma size was similar whether diagnosed >2 months prior, synchronously, or >2 months after BC. Meningioma was pathologically confirmed in 38% of BC-meningioma and 51% of meningioma patients. Distribution of BC histologies was comparable in patients with and without meningioma, with ductal type predominating (80% in BC-meningioma, 83% in BC). Although hormone receptor status of invasive BC was not significantly different between BC-meningioma and BC groups, the BC-meningioma cohort had fewer women with ER+/PR+ in situ disease (P=0.006). BC stage among women with meningioma was more advanced versus women with BC only.

Conclusions: Women with BC and meningioma have smaller-sized meningiomas and more advanced BCs compared with women having only 1 diagnosis. As there was no temporal relationship between size and latency between tumor diagnoses, the disparity in meningioma size between BC-meningioma and meningioma cohorts may have BC-associated biological components that warrant further study.

Department of Radiation Oncology, University of Rochester School of Medicine, Rochester, NY

The authors declare no conflicts of interest.

Reprints: Michael T. Milano, MD, PhD, Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Ave., Box 647, Rochester, NY 14642. Email: michael_milano@urmc.rochester.edu.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.